Sandoz Group AG (SDZ.SW) Stock

SDZ.SW logo

Sandoz Group AG

SDZ.SWSwitzerland
Healthcare

Company profile

Sandoz Group reported revenue of $11.16 billion for fiscal year 2025, up 7.4% from fiscal year 2024, and net income of $914.00 million. That is a net profit margin of 8.2% for fiscal year 2025. Other was its largest region in fiscal year 2025, with 66% of revenue. Our analysis of its filings shows revenue growing from $9.98 billion in fiscal year 2023 to $11.16 billion in fiscal year 2025, 5.7% a year on average. Sandoz Group reports about 20,000 full-time employees.

What stands out

  • Revenue and net income in fiscal year 2025 were the highest of the last 4 fiscal years.
  • It was founded in 1886.

Figures from company filings; latest fiscal year ended December 31, 2025.

About Sandoz Group AG

Sandoz Group AG develops, manufactures, and markets generic and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, supportive care, rare diseases, diabetes, immunology, endocrinology, neurology, osteoporosis, nephrology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company has a strategic collaboration with Shanghai Henlius Biotech, Inc. to broaden patient access to biosimilar medicines. Sandoz Group AG was founded in 1886 and is headquartered in Basel, Switzerland.

Largest shareholders

  • Sandoz Family Foundation4.15%
  • zCapital AG0.21%
  • Privatbank Von Graffenried AG0.20%
  • Berner Kantonalbank AG (Investment Management)0.17%
  • Mackenzie Investments Europe Ltd.0.14%

Share of the company, as of September 25, 2026

Leadership

  • Richard Saynor — Chief Executive Officer, 58
  • Claire D'Abreu-Hayling — Chief Scientific Officer & President of Generics Development, 61
  • Keren Haruvi — President of North America, 45
  • Remco J. Steenbergen — Chief Financial Officer, 57
  • Asaf Gal — Chief Technology Officer, 56

How much revenue does Sandoz Group make?

Sandoz Group reported $11.16 billion in revenue for fiscal year 2025, up 7.4% from $10.38 billion in fiscal year 2024.

Where does Sandoz Group make most of its revenue?

Other: 66% of revenue by region in fiscal year 2025, followed by United States (17%).

What companies are similar to Sandoz Group?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Curatis Holding AG (CURN.SW).

How has Sandoz Group's revenue changed over the last 4 fiscal years?

Revenue by fiscal year: FY2022, $9.31 billion; FY2023, $9.98 billion; FY2024, $10.38 billion; FY2025, $11.16 billion.

Company Information

SectorHealthcare
IndustryMulti-Therapeutic Drug Manufacturing
Employees20,000
Founded1886
IPO DateOct 4, 2023
IPO StatusPublic
HeadquartersBasel, Switzerland
FoundersAlfred Kern, Edouard Sandoz
ExchangeSwiss
TimezoneEurope/Zurich (CET)

Contact & Links

Address
Centralbahnstrasse 4, Basel, 4051
Phone
41 61 324 11 11
Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.

Data as of .

How to cite: DataPorium, “Sandoz Group AG (SDZ.SW)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/SDZ.SW

LinkedInLinkedInXXYouTubeYouTube